Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial
Zenas BioPharma, a clinical-stage global biopharmaceutical company, announced positive results from the Phase 2 MoonStone trial of obexelimab in Relapsing Multiple Sclerosis (RMS).
Obexelimab met its primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009.
Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009
Author summary: Zenas BioPharma reports positive trial results for obexelimab.
More News
- 2 US Navy aircraft crash in South China Sea
- The environmental impact of the 2026 World Cup
- Meet the Next Generation of Physician Leaders at Rutgers Health
- Elon Musk could step down if Tesla pay plan is rejected
- CRC Screening Improvements Decrease Mortality, but Disparities Persist
- Canada’s Lululemon Partners With National Football League
- Disparities in PsA Burden and Treatment Linked to Geographic and Social Factors
- John Cleese's European tour documentary to be shown at Clacton cinema
- ACT Brief: AI Partnerships, Global Trial Access, and a New Option for Menopause Symptoms | Applied Clinical Trials Online
- Prima retinal prosthesis tackles advanced macular degeneration